Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (979) Apply Human filter Veterinary (25) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (31) Apply Summaries of opinion filter Withdrawn applications (78) Apply Withdrawn applications filter Orphan designations (254) Apply Orphan designations filter Referrals (17) Apply Referrals filter

Product number

Patient safety

Yes (10) Apply Yes filter

Authorisation status

Authorised (649) Apply Authorised filter Refused (16) Apply Refused filter Withdrawn (98) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (18) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (154) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (35) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (22) Apply Yes filter

Compliance procedure number

Medicine type

Additional monitoring Remove Additional monitoring filter Conditional approval Remove Conditional approval filter Generic Remove Generic filter Orphan medicine Remove Orphan medicine filter Accelerated assessment (87) Apply Accelerated assessment filter Biosimilar (93) Apply Biosimilar filter Exceptional circumstances (61) Apply Exceptional circumstances filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

1006 results

Remove all filtersRemove all filters

Medicine type Generic Remove Generic filter Additional monitoring Remove Additional monitoring filter Conditional approval Remove Conditional approval filter Orphan medicine Remove Orphan medicine filter

Medicine Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter

Sort by

List item

Human medicine European public assessment report (EPAR): Rybrevant (updated)

amivantamab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 09/12/2021, , , Revision: 2, Authorised, Last updated: 30/11/2023
List item

Human medicine European public assessment report (EPAR): Yescarta (updated)

axicabtagene ciloleucel, Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018, , , Revision: 11, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Ranivisio (updated)

ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 25/08/2022, , , Revision: 2, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Zynlonta (updated)

loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell
Date of authorisation: 20/12/2022, , , Authorised, Last updated: 26/01/2023
List item

Human medicine European public assessment report (EPAR): Fingolimod Mylan (updated)

fingolimod hydrochloride , Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 18/08/2021, , Revision: 3, Authorised, Last updated: 26/01/2023
List item

Human medicine European public assessment report (EPAR): Coagadex (updated)

Human coagulation factor X, Factor X Deficiency
Date of authorisation: 16/03/2016, , , Revision: 9, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Paxlovid (updated)

nirmatrelvir, ritonavir, COVID-19 virus infection
Date of authorisation: 28/01/2022, , Revision: 8, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Tabrecta (updated)

capmatinib dihydrochloride monohydrate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/06/2022, , Revision: 1, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Dexmedetomidine Accord (updated)

dexmedetomidine, Premedication
Date of authorisation: 13/02/2020, , Revision: 6, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Herzuma (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 09/02/2018, , , Revision: 18, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): NexoBrid (updated)

proteolytic enzymes enriched in bromelain, Debridement
Date of authorisation: 18/12/2012, , , Revision: 14, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Comirnaty (updated)

Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020, , , Revision: 37, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Besremi (updated)

ropeginterferon alfa-2b, Polycythemia Vera
Date of authorisation: 15/02/2019, , Revision: 4, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Beovu (updated)

brolucizumab, Wet Macular Degeneration
Date of authorisation: 13/02/2020, , Revision: 6, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Trecondi (updated)

Treosulfan, Hematopoietic Stem Cell Transplantation
Date of authorisation: 20/06/2019, , Revision: 3, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Pelgraz (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 21/09/2018, , , Revision: 8, Authorised, Last updated: 23/01/2023
List item

Human medicine European public assessment report (EPAR): Alecensa (updated)

alectinib hydrochloride, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 16/02/2017, , Revision: 13, Authorised, Last updated: 23/01/2023
List item

Human medicine European public assessment report (EPAR): Filsuvez (updated)

dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w), Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional
Date of authorisation: 21/06/2022, , Revision: 1, Authorised, Last updated: 23/01/2023
List item

Human medicine European public assessment report (EPAR): Trepulmix (updated)

Treprostinil sodium, Hypertension, Pulmonary
Date of authorisation: 03/04/2020, , Revision: 3, Authorised, Last updated: 23/01/2023
List item

Human medicine European public assessment report (EPAR): Dasatinib Accord (updated)

dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 24/03/2022, , Revision: 1, Authorised, Last updated: 20/01/2023
List item

Human medicine European public assessment report (EPAR): Xofluza (updated)

Baloxavir marboxil, Influenza, Human
Date of authorisation: 07/01/2021, , Revision: 4, Authorised, Last updated: 19/01/2023
List item

Human medicine European public assessment report (EPAR): Pemetrexed Baxter (updated)

pemetrexed disodium heptahydrate, Carcinoma, Non-Small-Cell Lung; Mesothelioma
Date of authorisation: 09/12/2022, , Authorised, Last updated: 19/01/2023
List item

Human medicine European public assessment report (EPAR): Sarclisa (updated)

Isatuximab, Multiple Myeloma
Date of authorisation: 30/05/2020, , Revision: 6, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Venclyxto (updated)

Venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 04/12/2016, , Revision: 15, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Benlysta (updated)

belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011, , Revision: 29, Authorised, Last updated: 18/01/2023